Amylyx Pharmaceuticals (AMLX) Non-Current Assets (2021 - 2025)
Historic Non-Current Assets for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $9.4 million.
- Amylyx Pharmaceuticals' Non-Current Assets rose 7170.64% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year decrease of 6487.3%. This contributed to the annual value of $4.2 million for FY2024, which is 9203.99% down from last year.
- Amylyx Pharmaceuticals' Non-Current Assets amounted to $9.4 million in Q3 2025, which was up 7170.64% from $7.7 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' Non-Current Assets registered a high of $52.8 million during Q4 2023, and its lowest value of $663000.0 during Q4 2021.
- Over the past 5 years, Amylyx Pharmaceuticals' median Non-Current Assets value was $9.0 million (recorded in 2022), while the average stood at $13.1 million.
- Per our database at Business Quant, Amylyx Pharmaceuticals' Non-Current Assets surged by 130573.15% in 2022 and then tumbled by 9203.99% in 2024.
- Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Non-Current Assets stood at $663000.0 in 2021, then skyrocketed by 1305.73% to $9.3 million in 2022, then soared by 466.39% to $52.8 million in 2023, then plummeted by 92.04% to $4.2 million in 2024, then soared by 122.7% to $9.4 million in 2025.
- Its Non-Current Assets stands at $9.4 million for Q3 2025, versus $7.7 million for Q2 2025 and $3.5 million for Q1 2025.